{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:22:56Z","timestamp":1790727776419,"version":"4.1.0"},"reference-count":74,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Drug\u2013drug interactions (DDIs) involving hepatic organic anion transporting polypeptides 1B1\/1B3 (OATP1B) can be substantial, however, challenges remain for predicting interaction risk. Emerging evidence suggests that endogenous biomarkers, particularly coproporphyrin\u2010I (CP\u2010I), can be used to assess <jats:italic>in vivo<\/jats:italic> OATP1B activity. The present work under the International Consortium for Innovation and Quality in Pharmaceutical Development was aimed primarily at assessing CP\u2010I as a biomarker for informing OATP1B DDI risk. Literature and unpublished CP\u2010I data along with pertinent <jats:italic>in vitro<\/jats:italic> and clinical DDI information were collected to identify DDIs primarily involving OATP1B inhibition and assess the relationship between OATP1B substrate drug and CP\u2010I exposure changes. Static models to predict changes in exposure of CP\u2010I, as a selective OATP1B substrate, were also evaluated. Significant correlations were observed between CP\u2010I area under the curve ratio (AUCR) or maximum concentration ratio (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>R) and AUCR of substrate drugs. In general, the CP\u2010I <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>R was equal to or greater than the CP\u2010I AUCR. CP\u2010I <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>R\u2009&lt;\u20091.25 was associated with absence of OATP1B\u2010mediated DDIs (AUCR &lt;\u20091.25) with no false negative predictions. CP\u2010I <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>R\u2009&lt;\u20092 was associated with weak OATP1B\u2010mediated DDIs (AUCR &lt;\u20092). A correlation was identified between CP\u2010I exposure changes and OATP1B1 static DDI predictions. Recommendations for collecting and interpreting CP\u2010I data are discussed, including a decision tree for guiding DDI risk assessment. In conclusion, measurement of CP\u2010I is recommended to inform OATP1B inhibition potential. The current analysis identified changes in CP\u2010I exposure that may be used to prioritize, delay, or replace clinical DDI studies.<\/jats:p>","DOI":"10.1002\/cpt.3062","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T10:45:39Z","timestamp":1695725139000},"page":"1170-1183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Utilization of OATP1B Biomarker Coproporphyrin\u2010I to Guide Drug\u2013Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry"],"prefix":"10.1002","volume":"114","author":[{"given":"Ryota","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Quantitative, Translational and ADME Sciences, AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-9011","authenticated-orcid":false,"given":"Paresh P.","family":"Chothe","sequence":"additional","affiliation":[{"name":"Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. (TDCA)  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-9000","authenticated-orcid":false,"given":"Xiaoyan","family":"Chu","sequence":"additional","affiliation":[{"name":"ADME and Discovery Toxicology, Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Felix","family":"Huth","sequence":"additional","affiliation":[{"name":"PK Sciences, Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-9932","authenticated-orcid":false,"given":"Kazuya","family":"Ishida","sequence":"additional","affiliation":[{"name":"Drug Metabolism, Gilead Sciences Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Non\u2010Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, Eisai Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[{"name":"Departments of Drug Metabolism and Pharmacokinetics Bristol Myers Squibb Research and Development  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-9067","authenticated-orcid":false,"given":"Simone H.","family":"Stahl","sequence":"additional","affiliation":[{"name":"CVRM Safety, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-6329","authenticated-orcid":false,"given":"Manthena V.S.","family":"Varma","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Emilie","family":"Willemin","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetics, Janssen Research and Development, a Division of Janssen Pharmaceutica NV  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget L.","family":"Morse","sequence":"additional","affiliation":[{"name":"Department of Drug Disposition Eli Lilly  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"e_1_2_12_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.77"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.671"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00430.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.142"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002857"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.351"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011112-140309"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1823"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1749-4"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.04.003"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1554-0"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.234914"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1820"},{"key":"e_1_2_12_16_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions (CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2**)<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010investigation\u2010drug\u2010interactions\u2010revision\u20101_en.pdf> (2012) Accessed 28 March 2023."},{"key":"e_1_2_12_17_1","unstructured":"Ministry of Health Labour and Welfare.Guideline on drug interaction for drug development and appropriate provision of information (PSEHB notification No. 0723\u20104 dated July 23 2018). <https:\/\/www.pmda.go.jp\/files\/000228122.pdf> (2018). Accessed 28 March 2023."},{"key":"e_1_2_12_18_1","unstructured":"Food and Drug Administration.In vitro drug interaction studies \u2013 Cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/in\u2010vitro\u2010drug\u2010interaction\u2010studies\u2010cytochrome\u2010p450\u2010enzyme\u2010and\u2010transporter\u2010mediated\u2010drug\u2010interactions> (2020) Accessed 28 March 2023."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.723"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0792-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0156-z"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-016-0383-9"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.983"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.085241"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2434"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.012930"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059105"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000020"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052290"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.042"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.085993"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1216"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12672"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.081125"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2429"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2053"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.075531"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12625"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(69)90083-7"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1817"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.074740"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.232066"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0648-3"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1085111"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59526"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1695"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1261"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1599"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000620"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2593"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-022-00794-5"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2119"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2416-3"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2584"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.187"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253062"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13272"},{"key":"e_1_2_12_58_1","unstructured":"Lipitor\u00ae US Highlights of Prescribing Information. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020702Orig1s079correctedlbl.pdf> (2022). Accessed 28 April 2023."},{"key":"e_1_2_12_59_1","unstructured":"Crestor\u00ae US Highlights of Prescribing Information. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021366s043s044lbl.pdf> (2023). Accessed 28 April 2023."},{"key":"e_1_2_12_60_1","unstructured":"Zocor\u00ae US Highlights of Prescribing Information. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/019766Orig1s103lbl.pdf> (2023). Accessed 28 April 2023."},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12582"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.089474"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1998"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2829"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2643"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2672"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.434"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2184-5"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-0274"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.562566"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/004982597240767"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2017.1295171"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250500158175"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.04.001"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T15:10:34Z","timestamp":1700147434000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cpt.3062"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3062","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"2023-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}